[EATG Global HIV News daily digest] Digest #190-2009

[EATG Global HIV News daily digest]

Global HIV News Daily Digest

Copied as fair use  -  Ana  -





Latest Headlines




  Data
supporting boceprevir response guided therapy presented at American
Association for the Study of Liver Diseases (AASLD) Annual Meeting
  Hepatitis Tuesday 03 November 2009
					
  
Boceprevir response guided therapy utilizes a unique 4-week lead-in of
PEGINTRON(R) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP)
prior to the addition of boceprevir (800 mg TID) for an additional
24-44 weeks.
  SOURCE:
Schering-Plough Corporation




  How long does hepatitis B vaccine protection last?
  Hepatitis Tuesday 03 November 2009
					
  
The hepatitis B vaccine - given to protect against infection by a virus
that can cause severe liver damage and cancer - may protect for more
than two decades, according to a new study.
  SOURCE:
REUTERS




  EU attracting biobank research from US  
  EU Policy Tuesday 03 November 2009
					
  
The Netherlands and Luxembourg are battling to become the world's
biobank research hub, as Europe begins to attract multi-million euro
research projects from the US and beyond.
  SOURCE:
EurActiv.com




  Novartis looks to set up largest R&D centre in China 
  Pharma Industry Tuesday 03 November 2009
					
  
Novartis has announced plans to spend $1.25 billion to expand its research efforts in China.
  SOURCE:
PharmaTimes




  Industry must stop complaining and ‘reinvent innovation’ – Lilly CEO 
  Pharma Industry Tuesday 03 November 2009
					
  
The chief executive of Eli Lilly has been speaking about the need to
fix the “broken” engine of biopharma innovation and reverse the “loss
of trust in product safety and in the honesty of pharmaceutical
businesses”.
  SOURCE:
PharmaTimes




  IAS 2009 Impact Report 
  World Policy Tuesday 03 November 2009
					
  
Consistent with the focus of the IAS Conference series, the IAS 2009
Impact Report aims not only to highlight particularly important
original research and other developments detailed at IAS 2009, but to
analyze their potential impact on policy and practice. 
  SOURCE:
IAS




  Schering-Plough
reports potent antiviral activity with narlaprevir (SCH 900518), an
investigational, once-daily protease inhibitor for hepatitis C
  Hepatitis Tuesday 03 November 2009
					
  
Interim results of Phase IIa NEXT-I study presented at American
Association for the Study of Liver Diseases (AASLD) Annual Meeting.
  SOURCE:
Schering-Plough Corporation




  GlobeImmune’s hepatitis C therapeutic vaccine combined with standard of care increases end of treatment response rate by 15%
  Hepatitis Tuesday 03 November 2009
					
  
GI-5005 increased the end of treatment response in genotype 1
interferon-naïve patients to 74% when used in combination with standard
of care (SOC), pegylated interferon plus ribavirin, versus 59% for
patients receiving SOC alone. 
  SOURCE:
GlobeImmune Inc.




  Avila
presents data on its novel, orally-available protease inhibitor,
AVL-181, demonstrating viral clearance of hepatitis C virus in
preclinical models 
  Hepatitis Tuesday 03 November 2009
					
  
Potential for rapid and prolonged therapeutic benefit in HCV through protein silencing of NS3 protease. 
  SOURCE:
Avila Therapeutics, Inc.




  Millions die because of high malaria drug prices
  Tuberculosis & Malaria Tuesday 03 November 2009
					
  
Nearly a million people die from malaria each year because they cannot
afford the most effective treatment and instead often buy old drugs to
which the malaria parasite has become resistant, researchers said on
Monday.
  SOURCE:
REUTERS


----------------------------------------------------
DISCLAIMER
The articles in this digest represent a diversity of opinions on topics
of interest to the HIV treatment activist community. The EATG is not
responsible for their content. The articles posted in this digest do
not necessarily reflect EATG views or opinions.
FAIR USE NOTICE
The digest may contain copyrighted material which has not always been
specifically authorised by the copyright owner. Such material is made
available for educational purposes to advance the understanding of
scientific, ethical, legal and social issues. It is believed that this
constitutes a 'fair use' of any such copyrighted material. This
material is distributed without profit.


 

Information in this digest was accurately quoted during its compilation.




      
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://mail.eatg.org/pipermail/eatg-forum_eatg.org/attachments/20091103/366c5d5c/attachment-0001.html>